Multiple viruses can cause diseases in animals, many of these diseases are zoonoses. Veterinary vaccination is an effective way of preventing animal viral infection. In the face of animal viral infection, BioVenic provides comprehensive services of veterinary viral vaccine research and development, encompassing antigen discovery, formulation, vaccine safety and efficacy assessment. Leveraging advanced equipment and extensive experience, we ensure efficient vaccine design, development, and validation.
Fig.1 Veterinary Vaccine Development Process. (BioVenic Original)
Our Services
Veterinary Viral Vaccine Development Solution
As one of the most effective ways to control animal viral diseases, vaccination has gained great success. The main types of animal virus vaccines marketed globally are live attenuated and inactivated vaccines, both of which rely on traditional development methods. Based on the general development process, BioVenic provides the following services for veterinary viral vaccine development.
Viral Antigen Discovery
In the field of veterinary viral vaccine development, antigen discovery is at the forefront of our specialized services. Our services identify potential immunogens and validate their role in a robust immune response. In addition, through cutting-edge technology, we offer antigenic epitope identification services to provide critical information for effective vaccine design.
Viral Antigen Preparation
BioVenic is capable of inoculating the viral seed lots into chicken embryos (or cells), and cultures carefully to obtain allantoic fluid (or cell supernatant) containing live viruses. BioVenic also provides professional virus purification and inactivation/attenuation services as well as production of viral antigens like virus-like particle and recombinant viral surface proteins to ensure veterinary virus vaccine production safely and effectively.
Safety Assessment
In veterinary viral vaccine development, safety assessment is crucial. Our services include a comprehensive range of safety assessments, both in vitro and in vivo. The assessments are carefully designed to ensure that potential risks in the vaccine can be identified and provide guidance on improvements for subsequent development. Our trials are dedicated to regulatory compliance, ensuring your veterinary virus vaccines are scrutinized throughout the development.
Efficacy Assessment
Immunogenicity assessment is an important component in veterinary virus vaccine development. BioVenic assesses the immunogenicity of antigens through a series of in vitro and in vivo experiments. By measuring the levels of antigens, antibodies and cytokines, we help to evaluate the ability of vaccines to elicit a robust immune response.
Veterinary Viral Vaccine Development Platforms
In addition to the success achieved by live attenuated and inactivated vaccines, new technologies have been widely used developing safer and more effective veterinary viral vaccines, BioVenic has established advanced platforms to support you in the development of novel veterinary viral vaccines.
|
Platforms
|
Description
|
Advantage
|
Limitation
|
|
Gene-Deleted Attenuated Viral Vaccine
|
Deletion or inactivation of genes associated with pathogen virulence.
Relative service: CRISPR/Cas9 Genome Editing.
|
-
Strong and specific immune response.
|
-
Possible regain of toxicity through nucleic acid repair.
|
|
Recombinant Vectored Viral Vaccine
|
Genes for stimulating immunity cloned into vector viruses/bacteria.
Relative service: Virus Packaging.
|
-
Safe.
-
Strong and specific immune response.
-
Easy to manufacture.
|
-
Possible immune response to vector.
|
|
Subunit Viral Vaccine
|
Antigenic parts of pathogen.
Relative service: Recombinant Protein Customization.
|
-
Reduced side effects.
-
With multiple antigenic epitopes.
|
-
Lower immunogenicity.
-
Costly.
-
High requirements for storage and transportation.
|
|
Virus-like Particle Vaccine
|
Self-assembling virus structural subunits devoid of nucleic acids.
|
-
Safe.
-
High immune response.
|
-
Possible immune response to coated protein.
|
|
DNA Viral Vaccine
|
DNA coding for protective antigens.
Relative service: Plasmid DNA Construction.
|
-
Safe.
-
High immune response.
-
Simultaneous humoral and cellular immunity.
-
Low cost.
|
-
Limited to protein antigens.
-
Potential integration into animal genome.
-
Multiple inoculations required.
|
|
mRNA Viral Vaccine
|
mRNA coding for protective antigens.
Relative service: mRNA Synthesis.
|
-
Safe.
-
No interaction with genomic DNA.
-
Low cost.
-
Easy to design.
|
-
High requirements for storage and transportation.
|
Our Advantages
Wide Range of Animals
BioVenic develops virus vaccines for various animals, including livestock, poultry, aquaculture species, companion animals, to meet the immunization needs of different animal species.
Diverse Virus Expertise
We have the capability to work with a variety of animal viruses, from common pathogens to rare viruses.
Advanced Viral Vaccine Development Platforms
Our advanced platforms enable virus characterization and identification, antigen discovery and production, and vaccine safety and efficacy studies, which ensure the accuracy and reliability in different types of veterinary viral vaccine development.
Rich Experience
BioVenic has accumulated extensive expertise in virology, antigen discovery, protein expression, animal model development, and other relevant fields.
Ready to take the next step in promoting animal health? BioVenic is dedicated to providing veterinary virus vaccine development solutions that meet your needs. Contact us now, discuss how we can collaborate and realize your veterinary viral vaccine research and development program!
